* Panacea Biotec Limited approved standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025, on November 14, 2025. * The results were reviewed by the Audit Committee. * Standalone total income from operations for the quarter ended September 30, 2025, is ₹9,081 lakh compared to ₹7,664 lakh for the quarter ended September 30, 2024. * Consolidated total income from operations for the quarter ended September 30, 2025, is ₹14,113 lakh compared to ₹14,735 lakh for the quarter ended September 30, 2024. * The Group has recognised an exceptional income of ₹1,402 lakh (₹14.02 crore) which includes revenue of ₹858 lakh (₹8.58 crore) pursuant to the settlement agreement dated July 9, 2025, executed with Apotex Inc., USA. * Loss before tax for the half year ended September 30, 2025 is ₹2,977 lakh (₹29.77 crore) and the Group has incurred a loss (before tax and exceptional items) of ₹2,663 lakh (₹26.63 crore).
